22 Benevolo G, Stacchini A, Spina M et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood 2012; 120: 3222–3228. 23 Sarker D, Thirlwell C, Nelson M et al. Leptomeningeal
disease in AIDS-related non-Hodgkin’s lymphoma. AIDS 2003; 17: 861–865. 24 Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636. 25 Straus DJ, Huang J, Testa MA et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin’s lymphoma: analysis of AIDS RG7204 order Clinical Trials Group protocol
142–low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998; 16: 3601–3606. 26 Levine AM, Sullivan-Halley J, Pike MC et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991; 68: 2466–2472. 27 Kaplan LD, Lee JY, Ambinder RF et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106: 1538–1543. 28 Bower M, Gazzard B, Mandalia S et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma Acalabrutinib treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005;
143: 265–273. 29 Kassam S, Bower M, Lee SM et al. A retrospective, multicenter analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma. Leuk Lymphoma 2013; 54:1921–1927. 30 A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994. 31 Sehn Oxymatrine LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861. 32 Lim ST, Karim R, Tulpule A et al. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol 2005; 23: 8477–8482. 33 Kaplan LD, Straus DJ, Testa MA et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336: 1641–1648. 34 Mounier N, Spina M, Gabarre J et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006; 107: 3832–3840. 35 Dunleavy K, Little RF, Pittaluga S et al.